First use of the RANKL antibody denosumab in osteogenesis imperfecta Type VI

Journal of Musculoskeletal Neuronal Interactions

Volumn 12, Issue 3, 2012, Pages 183-188

  Semler, O ^a   Netzer, C ^a   Hoyer Kuhn, H ^a   Becker, J ^a   Eysel, P ^a   Schoenau, E ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

Author keywords

Denosumab; Osteogenesis imperfecta VI; Pigment epithelium derived factor; RANKL antibody; SERPINF 1

Indexed keywords

AMINO TERMINAL TELOPEPTIDE; CALCIUM; CREATININE; DENOSUMAB; DEOXYPYRIDINOLINE; NERIDRONIC ACID; OSTEOCLAST DIFFERENTIATION FACTOR; PAMIDRONIC ACID; PARATHYROID HORMONE; PROCOLLAGEN C PROTEINASE; VITAMIN D;

ADULT; ARTICLE; BONE BIOPSY; CASE REPORT; CHILD; COL1A1 GENE; COL1A2 GENE; GENE; GENE MUTATION; HUMAN; HUMAN TISSUE; MALE; MULTIPLE CYCLE TREATMENT; OSTEOGENESIS IMPERFECTA; OSTEOGENESIS IMPERFECTA TYPE VI; OSTEOLYSIS; PRESCHOOL CHILD; PROTEIN BLOOD LEVEL; SCHOOL CHILD; SERPINF1 GENE; SPINE SURGERY; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; VERTEBRA FRACTURE; VERTEBRA MALFORMATION;

ADOLESCENT; ANTIBODIES, MONOCLONAL, HUMANIZED; BONE AND BONES; BONE RESORPTION; CHILD; HUMANS; MALE; OSTEOGENESIS IMPERFECTA; RANK LIGAND;

EID: 84866340286     PISSN: 11087161     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Rauch F, Glorieux FH. Osteogenesis imperfecta. Lancet 2004;363:1377-1385.
2. Forlino A, Cabral WA, Barnes AM, Marini JC. New perspectives on osteogenesis imperfecta. Nat Rev Endocrinol 2011;7:540-557.
3. Glorieux FH, Bishop NJ, Plotkin H, Chabot G, Lanoue G, Travers R. Cyclic administration of pamidronate in children with severe osteogenesis imperfecta. N Engl J Med 1998;339:947-952.
4. Semler O, Beccard R, Palmisano D, et al. Reshaping of Vertebrae during Treatment with Neridronate or Pamidronate in Children with Osteogenesis Imperfecta. Horm Res Paediatr 2011;76:321-327.
5. Glorieux FH, Ward LM, Rauch F, et al. Osteogenesis imperfecta type VI: a form of brittle bone disease with a mineralization defect. J Bone Miner Res 2002;17:30-38.
6. Land C, Rauch F, Travers R, Glorieux FH. Osteogenesis imperfecta type VI in childhood and adolescence: effects of cyclical intravenous pamidronate treatment. Bone 2007;40:638-644.
7. Becker J, Semler O, Gilissen C, et al. Exome Sequencing Identifies Truncating Mutations in Human SERPINF1 in Autosomal-Recessive Osteogenesis Imperfecta. Am J Hum Genet 2011;88:362-371.
8. Homan EP, Rauch F, Grafe I, et al. Mutations in SERPINF1 cause osteogenesis imperfecta type VI. J Bone Miner Res 2011;26:2798-2803.
9. Rauch F, Husseini A, Roughley P, Glorieux FH, Moffatt P. Lack of circulating pigment epithelium-derived factor is a marker of osteogenesis imperfecta type VI. J Clin Endocrinol Metab 2012;97:E1550-E1556.
10. Akiyama T, Dass CR, Shinoda Y, et al. PEDF regulates osteoclasts via osteoprotegerin and RANKL. Biochem Biophys Res Commun 2009;391:789-794.
11. Cummings SR, San Martin J, McClung MR, et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 2009;361:756-765.
12. Iqbal J, Sun L, Zaidi M. Denosumab for the treatment of osteoporosis. Curr Osteoporos Rep 2010;8:163-167.
13. Gatti D, Antoniazzi F, Prizzi R, et al. Intravenous neridronate in children with osteogenesis imperfecta: a randomized controlled study. J Bone Miner Res 2005; 20:758-763.
14. McClung MR, Lewiecki EM, Cohen SB, et al. Denosumab in postmenopausal women with low bone mineral density. N Engl J Med 2006;354:821-831.
15. Orwoll ES, Bell NH, Nanes MS, et al. Collagen N-telopeptide excretion in men: the effects of age and intrasubject variability. J Clin Endocrinol Metab 1998;83:3930-3935.
16. Cintas HL, Siegel KL, Furst GP, Gerber LH. Brief assessment of motor function: reliability and concurrent validity of the Gross Motor Scale. Am J Phys Med Rehabil 2003;82:33-41.
17. Kendler DL, Roux C, Benhamou CL, et al. Effects of denosumab on bone mineral density and bone turnover in postmenopausal women transitioning from alendronate therapy. J Bone Miner Res 2010;25:72-81.
18. Sutjandra L, Rodriguez RD, Doshi S, et al. Population pharmacokinetic meta-analysis of denosumab in healthy subjects and postmenopausal women with osteopenia or osteoporosis. Clin Pharmacokinet 2011;50:793-807.
19. Yoon RS, Hwang JS, Beebe KS. Long-term bisphosphonate usage and subtrochanteric insufficiency fractures: a cause for concern? J Bone Joint Surg Br 2011;93:1289-1295.
20. Thompson RN, Phillips JR, McCauley SH, Elliott JR, Moran CG. Atypical femoral fractures and bisphosphonate treatment: experience in two large United Kingdom teaching hospitals. J Bone Joint Surg Br 2012;94:385-390.
21. Boyce A, Chong W, Yao J, et al. Denosumab treatment for fibrous dysplasia. J Bone Miner Res 2012;27:1462-1470.